Silence Therapeutics
SLN
59 hedge funds and large institutions have $60.6M invested in Silence Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 25 reducing their positions, and 11 closing their positions.
2.26% less ownership
Funds ownership: 17.73% → 15.47% (-2.3%)
9% less funds holding
Funds holding: 65 → 59 (-6)
28% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 25
43% less call options, than puts
Call options by funds: $4K | Put options by funds: $7K
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
64% less capital invested
Capital invested by funds: $168M → $60.6M (-$108M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$1.65M |
| 2 |
Morgan Stanley
New York
|
+$1.65M |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$1.14M |
| 4 |
Walleye Capital
New York
|
+$487K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$457K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.01M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$2.53M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.12M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.78M |
SLN Hedge Fund Activity: Q1 2025 in Review
59 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2025, worth a combined $60.6M — down 64% from $168M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SLN and 5 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 18 added.
The largest buyer was Saturn V Capital Management, adding an estimated $1.65M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $4.4M sold.
- 59 institutional investors held Silence Therapeutics (SLN) as of Q1 2025, down from 65 in Q4 2024.
- Funds reported $60.6M of Silence Therapeutics stock for Q1 2025, down 64% quarter-over-quarter.
- 5 funds opened new Silence Therapeutics positions in Q1 2025 and 11 closed out, a net change of -6 holders.
- The largest Silence Therapeutics buyer in Q1 2025 was Saturn V Capital Management, an estimated $1.65M added.
- The largest Silence Therapeutics seller in Q1 2025 was Eventide Asset Management, an estimated $4.4M sold.
Based on aggregated 13F filings for Q1 2025.